| Toggle Summary
|
Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman
|
|
| Toggle Summary
|
Intersect ENT Named One of Forbes Magazine’s “America’s Most Promising Companies” of 2014
|
|
| Toggle Summary
|
Intersect ENT to Present at the 32nd Annual J.P. Morgan Healthcare Conference
|
|
| Toggle Summary
|
Intersect ENT Named One of the “Fierce 15” Most Promising Private Companies by FierceMedicalDevices
|
|
| Toggle Summary
|
Intersect ENT Announces Positive Results from Pilot Study of Novel In-Office Implant for Chronic Sinusitis Patients
|
|
| Toggle Summary
|
Intersect ENT President and CEO Lisa Earnhardt Named One of Bay Area’s “Most Influential Women in Business”
|
|
| Toggle Summary
|
Intersect ENT Vice President Susan Stimson Honored As “Marketer That Matters”
|
|
| Toggle Summary
|
Intersect ENT Raises $30 Million Funds to Fuel Commercial Expansion and Development of Next Generation Products for Chronic Sinusitis Sufferers
|
|
| Toggle Summary
|
Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
|
|
| Toggle Summary
|
Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery
|
|
